Systematic benefit-risk study deems remdesivir a ‘favourable’ COVID-19 treatment
Study recorded all possible benefits and risks for COVID-19 patients receiving treatment
Read More
Tag: The Drug Safety Research Unit
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
